SciClone Pharma prices HK$2.2bn IPO at top end

Pharma_drugs_adobe_575x375.jpg
By Jonathan Breen
25 Feb 2021

SciClone Pharmaceuticals bagged HK$2.18bn ($281.2m) after pricing its IPO high on the back of storming demand from institutional and retail investors, according to sources close to the deal.

The issuer, which manufactures a possible treatment for Covid-19, hit the market at the end of last week with the first IPO in Hong Kong after the Chinese New Year holiday. On offer were 115.98m primary shares.

Sponsors CICC, Credit Suisse and Morgan Stanley launched the deal with ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial